ASH 2018 | Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, describes how a recent study found chronic lymphocytic leukemia (CLL) patients responded better to ibrutinib monotherapy if they only had a monoallelic TP53 aberration, compared to those with biallelic. Monoallelic TP53-mutated patients had better progression-free survival compared to biallelic patients. This knowledge has the potential to identify patients who would benefit from single-agent ibrutinib therapy and those who would not. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up